| Recruiting | PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors NCT07510828 | Beijing Biotech | Phase 1 / Phase 2 |
| Recruiting | A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors NCT07205718 | Takeda | Phase 1 / Phase 2 |
| Active Not Recruiting | A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or NCT06939283 | Werewolf Therapeutics, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors NCT06389526 | Coherus Oncology, Inc. | Phase 1 |
| Recruiting | Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors NCT06781983 | Innate Pharma | Phase 1 |
| Recruiting | A Phase 1 Study of LNCB74 in Advanced Solid Tumors NCT06774963 | NextCure, Inc. | Phase 1 |
| Recruiting | Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tum NCT06724016 | Hanmi Pharmaceutical Company Limited | Phase 1 |
| Recruiting | A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With NCT07260305 | Kangabio AUSTRALIA LTD PTY | Phase 1 |
| Recruiting | To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With L NCT06752681 | Day One Biopharmaceuticals, Inc. | Phase 1 |
| Recruiting | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies NCT06395519 | 858 Therapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combi NCT06448364 | Pfizer | Phase 1 |
| Active Not Recruiting | A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors NCT06548217 | Ono Pharmaceutical Co., Ltd. | Phase 1 |
| Terminated | A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors NCT06257758 | Valerio Therapeutics | Phase 1 / Phase 2 |
| Recruiting | A Phase 1 Study to Evaluate TGI-6 in Subjects With Locally Advanced/Metastatic Solid Tumors NCT06374173 | Hefei TG ImmunoPharma Co., Ltd. | Phase 1 |
| Recruiting | Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 NCT05957081 | PharmAbcine | Phase 1 |
| Recruiting | Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumo NCT06234397 | Hanmi Pharmaceutical Company Limited | Phase 1 |
| Active Not Recruiting | This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of NCT06074497 | Kangabio AUSTRALIA LTD PTY | Phase 1 |
| Unknown | Phase I of XKH002 Injection in Patients NCT06196762 | Zhejiang Kanova Biopharmaceutical Co., LTD | Phase 1 |
| Recruiting | A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors NCT06248411 | Kyowa Kirin Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations NCT05907304 | Erasca, Inc. | Phase 1 |
| Recruiting | DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors NCT05785754 | DynamiCure Biotechnology | Phase 1 |
| Recruiting | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors NCT05787587 | IDEAYA Biosciences | Phase 1 |
| Recruiting | A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies NCT05753722 | Incendia Therapeutics | Phase 1 |
| Completed | Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid NCT05848466 | Bio-Thera Solutions | Phase 1 |
| Terminated | A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors NCT05716295 | Medikine, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors NCT05652855 | Minghui Pharmaceutical Pty Ltd | Phase 1 / Phase 2 |
| Recruiting | Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors NCT05693844 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Recruiting | Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors NCT05598151 | Hanmi Pharmaceutical Company Limited | Phase 1 |
| Completed | A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK NCT05594043 | Merck Sharp & Dohme LLC | Phase 1 |
| Unknown | A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With NCT05483530 | Shanghai Henlius Biotech | Phase 1 |
| Completed | WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma NCT05678998 | Werewolf Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With A NCT05538130 | Pfizer | Phase 1 |
| Terminated | DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors NCT05496595 | DynamiCure Biotechnology | Phase 1 |
| Active Not Recruiting | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectab NCT05572684 | NextCure, Inc. | Phase 1 / Phase 2 |
| Unknown | To Evaluate the Safety and Tolerability of SYHX2001 in Patients With Advanced or Metastatic Solid Tumors NCT05407909 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors NCT05399654 | Tallac Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic So NCT05382325 | Merck Sharp & Dohme LLC | Phase 1 |
| Terminated | A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors NCT05388279 | Shanghai Junshi Bioscience Co., Ltd. | Phase 1 |
| Unknown | A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114 NCT05200273 | Akeso | Phase 1 |
| Withdrawn | A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metast NCT04430933 | NextCure, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembroli NCT05017012 | Merck Sharp & Dohme LLC | Phase 1 |
| Unknown | A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors NCT04843709 | Shanghai Miracogen Inc. | Phase 1 / Phase 2 |
| Terminated | A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors NCT04875806 | NextCure, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Sol NCT04866134 | Erasca, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors NCT04670679 | Erasca, Inc. | Phase 1 |
| Completed | A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors NCT04572152 | Akeso | Phase 1 |
| Terminated | A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer NCT04586270 | Taiho Oncology, Inc. | Phase 1 |
| Completed | A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors NCT04381650 | Takeda | Phase 1 / Phase 2 |
| Terminated | A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor NCT04427774 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Terminated | A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors NCT04408599 | NextCure, Inc. | Phase 1 / Phase 2 |
| Terminated | Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FI NCT04003623 | Incyte Corporation | Phase 2 |
| Completed | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tum NCT03849469 | Xencor, Inc. | Phase 1 |
| Completed | First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjec NCT03616574 | Holy Stone Healthcare Co., Ltd | Phase 1 |
| Terminated | Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cu NCT03684785 | Exicure, Inc. | Phase 1 / Phase 2 |
| Completed | Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors NCT03730337 | Ono Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors NCT03665285 | NextCure, Inc. | Phase 1 / Phase 2 |
| Terminated | Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors NCT03454243 | Hoffmann-La Roche | EARLY_Phase 1 |
| Terminated | A Study of a New Investigational Medicinal Product to Treat Patients with Advanced or Metastatic Solid Tumors NCT03316638 | Pierre Fabre Medicament | Phase 1 / Phase 2 |
| Completed | A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors NCT03248843 | 3D Medicines (Sichuan) Co., Ltd. | Phase 1 |
| Active Not Recruiting | Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors NCT03155061 | Ono Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours NCT03082053 | ASLAN Pharmaceuticals | Phase 1 |
| Completed | A Phase I Study of TAS-102 in Solid Tumors NCT02261532 | Taiho Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic S NCT01928394 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Completed | Phase I Clinical Study of Metatinib Tromethamine Tablet NCT02004548 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 1 |
| Terminated | E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With NCT01355302 | Eisai Inc. | Phase 1 / Phase 2 |
| Terminated | A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of NCT01506934 | Abbott | Phase 1 |
| Completed | Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors NCT02220049 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 1 |
| Completed | Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors NCT01014429 | Nerviano Medical Sciences | Phase 1 |
| Completed | A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Brea NCT00748553 | University of Utah | Phase 1 / Phase 2 |
| Completed | A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patien NCT00907205 | Semafore Pharmaceuticals | Phase 1 |
| Completed | A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors NCT00276913 | Synta Pharmaceuticals Corp. | Phase 1 |